The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Forecasted Market Value Of The Ribonucleic Acid Interference (RNAi) Technology Market Across 2026–2030?
The ribonucleic acid interference (rnai) technology market size has experienced rapid expansion in recent years. Its valuation is anticipated to climb from $4.43 billion in 2025 to $5.14 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.9%. This historical growth can be linked to improvements in molecular biology research, initial positive clinical results for rnai therapeutics, the broadening of academic gene research endeavors, the presence of effective screening libraries, and the flourishing of biotech innovation ecosystems.
The market for ribonucleic acid interference (rnai) technology is projected to undergo substantial expansion in the coming years. It is forecast to grow to $9.19 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.6%. This anticipated growth can be attributed to several factors during the forecast period, including the increasing commercialization of RNAi-based medications, a rise in investments targeting rare disease therapeutics, the expansion of nanoparticle delivery methods, the growth of pharmaceutical partnerships, and greater regulatory acceptance for gene-silencing treatments. Key trends for the forecast period involve a growing embrace of gene silencing therapies, increased utilization of siRNA-based drug platforms, the evolving integration of RNAi into precision medicine, the broadening of targeted genetic disease treatments, and enhanced optimization of delivery systems.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30371&type=smp
What Primary Drivers Are Shaping The Development Of The Ribonucleic Acid Interference (RNAi) Technology Market?
The future expansion of the ribonucleic acid interference (RNAi) technology market is anticipated, fueled by the rising need for targeted therapeutics. These therapies precisely address molecular irregularities in conditions like cancer or other diseases, enhancing treatment accuracy and reducing damage to healthy cells. The increased emphasis on targeted treatments stems mainly from progress in precision medicine, allowing for customized and more potent therapies tailored to unique genetic makeups. Ribonucleic Acid Interference (RNAi) Technology boosts the call for targeted therapeutics by facilitating exact gene silencing for the treatment of genetic and rare diseases. This technology aids in creating highly specific and efficacious treatments, thereby stimulating innovation within personalized medicine. For instance, in December 2024, the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, reported that the Food and Drug Administration (FDA) approved 6 gene therapy products in 2023, an increase from 5 approvals in 2022. Consequently, the growing requirement for targeted therapeutics is propelling the expansion of the ribonucleic acid interference (RNAi) technology market.
What Segmentation Levels Are Considered In The Ribonucleic Acid Interference (RNAi) Technology Market?
The ribonucleic acid interference (rnai) technology market covered in this report is segmented –
1) By Product: Micro Ribonucleic Acid (miRNA), Small Interfering Ribonucleic Acid (siRNA), Other Products
2) By Delivery Method: Viral Vectors, Nanoparticles, Chemical Modifications, Physical Methods
3) By Application: Therapeutics, Drug Discovery, Agriculture, Diagnostics
4) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations (CROs) And Contract Manufacturing Organizations (CMOs)
Subsegments:
1) By Micro Ribonucleic Acid (miRNA): Micro Ribonucleic Acid Mimics, Micro Ribonucleic Acid Inhibitors, Micro Ribonucleic Acid Expression Vectors, Micro Ribonucleic Acid Profiling And Quantification Kits
2) By Small Interfering Ribonucleic Acid (siRNA): Small Interfering Ribonucleic Acid Synthetic Duplexes, Small Interfering Ribonucleic Acid Dicer Substrate Molecules, Small Interfering Ribonucleic Acid Self Delivering Conjugates, Small Interfering Ribonucleic Acid N Acetylgalactosamine Conjugates
3) By Other Products: Short Hairpin Ribonucleic Acid Expression Constructs, Ribonucleic Acid Interference Screening Libraries, Ribonucleic Acid Interference Transfection Reagents, Micro Ribonucleic Acid And Small Interfering Ribonucleic Acid Research Kits
What Trends Are Projected To Affect The Ribonucleic Acid Interference (RNAi) Technology Market?
Major companies operating in the ribonucleic acid interference (RNAi) technology market are concentrating on integrating platforms, such as strategic financing and support, to streamline the development, delivery, and commercialization of RNA interference (RNAi) therapeutics. This effort aims to establish a sustainable pipeline of numerous programs across diverse disease areas. Strategic financing and support refer to acquiring investment and resources from venture capital, industry partners, and other stakeholders to accelerate the research, development, and market introduction of RNA interference (RNAi) therapeutics. For example, in October 2024, City Therapeutics Inc., a US-based biopharmaceutical company, received $135 million in Series A financing led by ARCH Venture Partners, with additional investment from other leading life sciences investors, to drive the future of RNA interference (RNAi)-based medicine. This funding will facilitate the advancement of RNAi-based medicine by leveraging its proprietary lipid nanoparticle (LNP) delivery platform, engineered to precisely target tissues beyond the liver. This platform seeks to overcome a significant historical limitation in the field, enabling the development of therapies for a wider array of genetic disorders.
Which Leading Firms Are Contributing To The Growth Of The Ribonucleic Acid Interference (RNAi) Technology Market?
Major companies operating in the ribonucleic acid interference (rnai) technology market are F. Hoffmann-La Roche AG, Merck KGaA, Novartis AG, Thermo Fisher Scientific Inc., Danaher Corporation, Revvity Inc., QIAGEN N.V., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., GenScript Biotech Corporation, Promega Corporation, Arrowhead Pharmaceuticals Inc., Silence Therapeutics plc, Creative Biolabs Inc., Bioneer Corporation, Genevant Sciences Ltd., Gradalis Inc., Altogen Labs LLC, Sirnaomics Inc., Altogen Biosystems Inc.
Read the full ribonucleic acid interference (rnai) technology market report here:
How Does The Ribonucleic Acid Interference (RNAi) Technology Market Perform Across Major Global Regions?
North America was the largest region in the ribonucleic acid interference (RNAi) technology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid interference (rnai) technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Ribonucleic Acid Interference (RNAi) Technology Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=30371&type=smp
Browse Through More Reports Similar to the Global Ribonucleic Acid Interference (RNAi) Technology Market 2026, By The Business Research Company
Ribonucleic Acid Rna Sequencing Market Report 2026
Nucleic Acid Isolation And Purification Market Report 2026
Ribose Nucleic Acid Rna Based Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model